Skip to main content
SpringerLink
Log in

Metabolic Response Evaluation by PET During Neoadjuvant Treatment for Adenocarcinoma of the Esophagus and Esophagogastric Junction

  • Chapter
  • First Online:
Adenocarcinoma of the Esophagogastric Junction

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 182))

Abstract

Following several randomized trials, neoadjuvant therapy in adenocarcinoma of esophagus and the esophagogastric junction can be seen as an international standard. However, in a large proportion of patients the objective response achieved is unsatisfactory. These patients do not benefit from neoadjuvant therapy, but do suffer from toxic side effects; sometimes progressive and appropriate surgical therapy is delayed. For this reason, a diagnostic test that can accurately assess tumor response to neoadjuvant therapy might be of crucial importance. Response evaluation using CT scan, endoluminal ultrasound, or rebiopsy is not reliable. In recent times, response evaluation using 18FGD PET after and during neoadjuvant treatment is in the focus of clinical and scientific interest. Most studies have evaluated the diagnostic modalities for response to neoadjuvant treatment after completion of the treatment. Following the published data so far, FDG-PET seems to be less accurate after and during chemoradlatlon than after chemotherapy alone. The data of early response evaluation (14 days after the onset of chemotherapy) are very much encouraging; however, they have to be evaluated in an international randomized trial. Standardization of PET technology as well as defining the thresholds used for the estimation of early response is mandatory. So far, FDG-PET does not change treatment In esophageal and gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ajani JA, Komaki R, Putnam JB et al (2001) A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:279–286

    Article  PubMed  CAS  Google Scholar 

  • Ajani JA, Moiseyenko VM, Tjulandin S et al (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3205–3209

    Article  PubMed  CAS  Google Scholar 

  • Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530

    Article  PubMed  Google Scholar 

  • Bhargava P, Reich P, Alavi A et al (2003) Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med 28:849–850

    Article  PubMed  Google Scholar 

  • Boige V, Pignon JP, Saint-Aubert B, Lasser P, Conroy T, Bouché O, Segol P, Bedenne L, Rougier P, Ychou M (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25(18S):4510 abstract

    Google Scholar 

  • Bösing N, Schumacher B, Frieling T et al (2003) Endosonographie in der klinischen Routine beim Adenokarzinom des distalen Ösophagus und Magens. Chirurg 74:214–221

    Article  PubMed  Google Scholar 

  • Bruzzi JF, Swisher SG, Truong MT et al (2007) Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109:125–134

    Article  PubMed  Google Scholar 

  • Cerfolia RJ et al (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129:1232–1241

    Article  PubMed  Google Scholar 

  • Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Article  PubMed  CAS  Google Scholar 

  • Daly JM, Fry WA, Little AG et al (2000) Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 190:562–572

    Article  PubMed  CAS  Google Scholar 

  • Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361–368

    Article  PubMed  CAS  Google Scholar 

  • Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234

    Article  PubMed  CAS  Google Scholar 

  • Griffith JF, Chan AC, Chow LT et al (1999) Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 72:678–684

    PubMed  CAS  Google Scholar 

  • Hautzel H, Muller-Gartner HW (1997) Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 38:1384–1386

    PubMed  CAS  Google Scholar 

  • Hoekstra CJ, Paglianiti I, Hoekstra OS et al (2000) Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27:731–743

    Article  PubMed  CAS  Google Scholar 

  • Jones DR, Parker LA Jr, Detterbeck FC et al (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85:1026–1032

    Article  PubMed  CAS  Google Scholar 

  • Levine EA, Farmer MR, Clark P et al (2006) Pre­dictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243:472–478

    Article  PubMed  Google Scholar 

  • Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805

    Article  PubMed  Google Scholar 

  • Lowy AM, Mansfield PF, Leach SD et al (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229:303–308

    Article  PubMed  CAS  Google Scholar 

  • Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680–2686

    Article  PubMed  CAS  Google Scholar 

  • McLoughlin JM, Melis M, Siegel EM et al (2008) Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg 206:879–886

    Article  PubMed  Google Scholar 

  • Medical Research Council Oesophageal Cancer Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727–1733

    Article  Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  • Munden RF, Macapinlac HA, Erasmus JJ (2006) Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 21:137–145

    Article  PubMed  Google Scholar 

  • Nakamura R, Obara T, Katsuragawa S et al (2002) Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 20:181–186

    PubMed  Google Scholar 

  • Ott K, Sendler A, Becker K et al (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU and leucovorin (PLF) in locally advanced gastric cancer – a Prospective Phase II Study. Gastric Cancer 6:159–167

    Article  PubMed  CAS  Google Scholar 

  • Ott K, Weber W, Siewert JR (2006a) The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 19:433–442

    Article  PubMed  CAS  Google Scholar 

  • Ott K, Weber WA, Lordick F et al (2006b) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692–4698

    Article  PubMed  Google Scholar 

  • Ott K, Herrmann K, Lordick F et al (2008a) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14:2012–2018

    Article  PubMed  CAS  Google Scholar 

  • Ott K, Lordick F, Herrmann K et al (2008b) The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer 11:1–9

    Article  PubMed  Google Scholar 

  • Park JO, Lee SI, Song SY et al (2003) Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33:533–537

    Article  PubMed  Google Scholar 

  • Phelps ME (2000) Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97:9226–9233

    Article  PubMed  CAS  Google Scholar 

  • Schneider PM, Metzger R, Schaefer H et al (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 248:902–908

    Article  PubMed  Google Scholar 

  • Sendler A, Siewert JR (2003) Individualizing therapy in gastric cancer. Expert Rev Anticancer Ther 3:457–470

    Article  PubMed  CAS  Google Scholar 

  • Shah MA, Yeung HW, Coit D, Trocola R, Ilson D, Randazzo J (2007) A phase II study of preoperative chemotherapy with irinotecan and cisplatin for gastric cancer (NCI 5917): FDG-PET predicts patient outcome. J Clin Oncol 25:4502 abstract

    Google Scholar 

  • Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77

    PubMed  CAS  Google Scholar 

  • Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459

    Article  PubMed  CAS  Google Scholar 

  • Siewert JR, Lordick F, Ott K et al (2007) Induction chemotherapy in Barrett cancer: influence on ­surgical risk and outcome. Ann Surg 246:624–628

    Article  PubMed  Google Scholar 

  • Smithers BM, Couper GC, Thomas JM et al (2008) Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 21:151–158

    Article  PubMed  CAS  Google Scholar 

  • Stahl M, Stuschke M, Lehmann N et al (2005a) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310–2317

    Article  PubMed  Google Scholar 

  • Stahl M, Wilke H, Stuschke M et al (2005b) Clinical response to induction chemotherapy predicts local control and long-term survival in ­multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 131:67–72

    Article  PubMed  Google Scholar 

  • Stein HJ, Sendler A, Fink U et al (2000) Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 80:659–682

    Article  PubMed  CAS  Google Scholar 

  • Swisher SG, Erasmus J, Maish M et al (2004a) 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101:1776–1785

    Article  PubMed  Google Scholar 

  • Swisher SG, Maish M, Erasmus JJ et al (2004b) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78:1152–1160

    Article  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  • Vallböhmer D, Hölscher AH, Schmidt M, Bollschweiler E, Baldus S, Mönig S, etzger R, chneider PM, Dietlein M (2008) Limitations of positron emission tomography in predicting histopathologic response or prognosis following neoadjuvant chemoradiation for esophageal cancer. J Clin Oncol 26:4529 abstract

    Google Scholar 

  • Walker SJ, Allen SM, Steel A et al (1991) Assessment of the response to chemotherapy in oesophageal cancer. Eur J Cardiothorac Surg 5:519–522

    Article  PubMed  CAS  Google Scholar 

  • Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065

    PubMed  CAS  Google Scholar 

  • Westerterp M, Van Westreenen HL, Reitsma JB et al (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review. Radiology 236:841–851

    Article  PubMed  Google Scholar 

  • Wieder HA, Beer AJ, Lordick F et al (2005) Com­parison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46:2029–2034

    PubMed  CAS  Google Scholar 

  • Yoshida S, Miyata Y, Ohtsu A et al (2000) Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 3:128–133

    Article  PubMed  Google Scholar 

  • Young H, Baum R, Cremerius U et al (1999) Measu­rement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organiza­tion for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Allgemein-, Viszeral- und Tumorchirurgie, Isar Medizin Zentrum, Sonnenstr. 24 - 26, 80331, München, Germany

    A. Sendler

Authors
  1. A. Sendler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Sendler .

Editor information

Editors and Affiliations

  1. Klinik für Viszeral- und, Transplantationschirurgie, Universitätsspital Zürich, Rämistr. 100, Zürich, 8091, Switzerland

    Paul M. Schneider

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Sendler, A. (2009). Metabolic Response Evaluation by PET During Neoadjuvant Treatment for Adenocarcinoma of the Esophagus and Esophagogastric Junction. In: Schneider, P. (eds) Adenocarcinoma of the Esophagogastric Junction. Recent Results in Cancer Research, vol 182. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70579-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-70579-6_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-70578-9

  • Online ISBN: 978-3-540-70579-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation